Citigroup’s VanEck Pharmaceutical ETF PPH Stock Holding History

Citigroup’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.8M	Buy	318,604 +98,980	+45%	+$10.2M	0.01%	895
2026 Q1	$22.8M	Sell	219,624 -1,109,217	-83%	-$118M	0.01%	994
2025 Q4	$137M	Buy	1,328,841 +610,642	+85%	+$59.4M	0.06%	282
2025 Q3	$64.9M	Buy	718,199 +652,175	+988%	+$57.1M	0.03%	535
2025 Q2	$5.81M	Buy	+66,024	New	+$5.72M	﹤0.01%	1766
2025 Q1	–	Sell	-413	Closed	-$35.6K	–	5869
2024 Q4	$35.6K	Buy	+413	New	+$37.4K	﹤0.01%	5170
2024 Q3	–	Sell	-200	Closed	-$18.3K	–	5777
2024 Q2	$18.3K	Hold	200	–	–	﹤0.01%	5032
2024 Q1	$18.1K	Hold	200	–	–	﹤0.01%	5060
2023 Q4	$16.3K	Hold	200	–	–	﹤0.01%	5055
2023 Q3	$16K	Sell	200 -8,067	-98%	-$651K	﹤0.01%	4448
2023 Q2	$651K	Buy	8,267 +5,174	+167%	+$405K	﹤0.01%	3178
2023 Q1	$240K	Buy	3,093 +1,785	+136%	+$138K	﹤0.01%	3625
2022 Q4	$102K	Buy	1,308 +1,108	+554%	+$81.7K	﹤0.01%	4015
2022 Q3	$13K	Sell	200 -183	-48%	-$13.5K	﹤0.01%	4905
2022 Q2	$29K	Buy	383 +183	+92%	+$14.3K	﹤0.01%	4803
2022 Q1	$16K	Hold	200	–	–	﹤0.01%	5280
2021 Q4	$15K	Sell	200 -100	-33%	-$7.44K	﹤0.01%	5477
2021 Q3	$22K	Sell	300 -135	-31%	-$10.1K	﹤0.01%	5201
2021 Q2	$32K	Hold	435	–	–	﹤0.01%	5050
2021 Q1	$30K	Hold	435	–	–	﹤0.01%	5008
2020 Q4	$29K	Hold	435	–	–	﹤0.01%	6418
2020 Q3	$27K	Sell	435 -2	-0.5%	-$126	﹤0.01%	5986
2020 Q2	$27K	Buy	437 +100	+30%	+$6.05K	﹤0.01%	6385
2020 Q1	$18K	Hold	337	–	–	﹤0.01%	6762
2019 Q4	$22K	Hold	337	–	–	﹤0.01%	6894
2019 Q3	$19K	Hold	337	–	–	﹤0.01%	6768
2019 Q2	$20K	Hold	337	–	–	﹤0.01%	7089
2019 Q1	$20K	Hold	337	–	–	﹤0.01%	6966
2018 Q4	$19K	Sell	337 -200,000	-100%	-$12.1M	﹤0.01%	6903
2018 Q3	$12.9M	Hold	200,337	–	–	0.01%	1114
2018 Q2	$11.8M	Sell	200,337 -17,500	-8%	-$1.01M	0.01%	1164
2018 Q1	$12.3M	Buy	217,837 +2	+0%	+$120	0.01%	1096
2017 Q4	$12.9M	Buy	217,835 +17,500	+9%	+$1M	0.01%	1100
2017 Q3	$11.6M	Hold	200,335	–	–	0.01%	1135
2017 Q2	$11.8M	Sell	200,335 -350,965	-64%	-$19.9M	0.01%	1040
2017 Q1	$30.4M	Buy	551,300 +200,690	+57%	+$10.9M	0.03%	564
2016 Q4	$18.4M	Sell	350,610 -300,000	-46%	-$16M	0.02%	821
2016 Q3	$37.4M	Buy	650,610 +649,855	+86,074%	+$39M	0.03%	437
2016 Q2	$44K	Sell	755 -961	-56%	-$56K	﹤0.01%	5650
2016 Q1	$98K	Sell	1,716 -49,825	-97%	-$2.95M	﹤0.01%	5676
2015 Q4	$3.37M	Sell	51,541 -491	-0.9%	-$31.7K	﹤0.01%	2055
2015 Q3	$3.28M	Buy	52,032 +693	+1%	+$48.7K	﹤0.01%	2025
2015 Q2	$3.63M	Hold	51,339	–	–	﹤0.01%	2016
2015 Q1	$3.61M	Sell	51,339 -313	-0.6%	-$21.2K	﹤0.01%	2013
2014 Q4	$3.32M	Buy	51,652 +945	+2%	+$60.2K	﹤0.01%	2094
2014 Q3	$3.22M	Buy	50,707 +50,360	+14,513%	+$3.12M	﹤0.01%	2194
2014 Q2	$22K	Sell	347 -3	-0.9%	-$178	﹤0.01%	5763
2014 Q1	$20K	Sell	350 -82	-19%	-$4.64K	﹤0.01%	6025
2013 Q4	$23K	Buy	432 +177	+69%	+$8.96K	﹤0.01%	6123
2013 Q3	$12K	Buy	255 +152	+148%	+$7.21K	﹤0.01%	6141
2013 Q2	$5K	Buy	+103	New	+$4.76K	﹤0.01%	6313

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Citigroup's PPH Position: Q2 2026 in Review

Citigroup increased its VanEck Pharmaceutical ETF (PPH) stake by 45% in Q2 2026, buying an estimated $10.2M and bringing the position to 318,604 shares worth $34.8M. The position accounts for 0.01% of the portfolio, ranked #895.

Citigroup first reported a position in PPH in Q2 2013 and has held it in 51 quarters since. The position peaked at $137M in Q4 2025. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Citigroup held 318,604 shares of VanEck Pharmaceutical ETF worth $34.8M as of Q2 2026.
Citigroup bought 98,980 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $10.2M.
VanEck Pharmaceutical ETF made up 0.01% of Citigroup's portfolio in Q2 2026, its #895 holding.
Citigroup first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and has held it in 51 quarters since.
Citigroup's VanEck Pharmaceutical ETF position peaked at $137M in Q4 2025.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.